| Paul M Shipkin, MD, PC | |
|
101 Greenwood Ave Ste 450, Jenkintown, PA 19046-2627 | |
| (215) 293-9140 | |
| (215) 293-9143 |
| Full Name | Paul M Shipkin |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 53 Years |
| Location | 101 Greenwood Ave Ste 450, Jenkintown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013960764 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | MD 014493E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doylestown Hospital | Doylestown, PA | Hospital |
| Entity Name | Paul M Shipkin M.d., P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245669860 PECOS PAC ID: 8224269410 Enrollment ID: O20140402000070 |
News Archive
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride (HCl) Tablets, 5 mg and 10 mg, the generic version of Eisai's Aricept Tablets, which are used to treat dementia associated with Alzheimer's disease.
A new discovery about selective serotonin reuptake inhibitors (SSRIs) suggests that these drugs, which are used to treat mental health disorders like depression and anxiety, have multiple effects on our cells. In a research report published in the August 2010 issue of GENETICS, researchers used yeast cells to identify secondary drug targets or pathways affected by SSRIs. Such secondary pathways could help explain why different people taking the same drug may experience different effects, and could also lead to new types of drugs altogether.
Interested in seeing the future of Navy and Marine Corps technology? Want to discuss research opportunities with some of the brightest minds in the military, federal government, industry and academia?
Researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), have identified a promising new target for autoimmune disease treatment - a cell-surface receptor called DR3.
› Verified 4 days ago
| Entity Name | University Of Penn - Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235527342 PECOS PAC ID: 6204730955 Enrollment ID: O20141111000091 |
News Archive
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride (HCl) Tablets, 5 mg and 10 mg, the generic version of Eisai's Aricept Tablets, which are used to treat dementia associated with Alzheimer's disease.
A new discovery about selective serotonin reuptake inhibitors (SSRIs) suggests that these drugs, which are used to treat mental health disorders like depression and anxiety, have multiple effects on our cells. In a research report published in the August 2010 issue of GENETICS, researchers used yeast cells to identify secondary drug targets or pathways affected by SSRIs. Such secondary pathways could help explain why different people taking the same drug may experience different effects, and could also lead to new types of drugs altogether.
Interested in seeing the future of Navy and Marine Corps technology? Want to discuss research opportunities with some of the brightest minds in the military, federal government, industry and academia?
Researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), have identified a promising new target for autoimmune disease treatment - a cell-surface receptor called DR3.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul M Shipkin, MD, PC 101 Greenwood Ave, Ste 450, Jenkintown, PA 19046-2627 Ph: (215) 293-9140 | Paul M Shipkin, MD, PC 101 Greenwood Ave Ste 450, Jenkintown, PA 19046-2627 Ph: (215) 293-9140 |
News Archive
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride (HCl) Tablets, 5 mg and 10 mg, the generic version of Eisai's Aricept Tablets, which are used to treat dementia associated with Alzheimer's disease.
A new discovery about selective serotonin reuptake inhibitors (SSRIs) suggests that these drugs, which are used to treat mental health disorders like depression and anxiety, have multiple effects on our cells. In a research report published in the August 2010 issue of GENETICS, researchers used yeast cells to identify secondary drug targets or pathways affected by SSRIs. Such secondary pathways could help explain why different people taking the same drug may experience different effects, and could also lead to new types of drugs altogether.
Interested in seeing the future of Navy and Marine Corps technology? Want to discuss research opportunities with some of the brightest minds in the military, federal government, industry and academia?
Researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), have identified a promising new target for autoimmune disease treatment - a cell-surface receptor called DR3.
› Verified 4 days ago